Efficacy and Safety of Tracnil™ Administration in Patients with Dermatological Manifestations of PCOS: An Open-Label Single-Arm Study

Table 4

The endocrine and metabolic assessment of patients before and after the treatment with Tracnil™.

Group	Testosterone total (ng/dl)	Testosterone free (pg/ml)	Androstenedione (ng/ml)
Before	34.10 ± 2.83	2.681 ± 0.264	1.637 ± 0.163
After	29.94 ± 2.91	2.754 ± 0.229	1.43 ± 0.178

Data shown as mean ± SEM for a sample size of N = 32 patients. Student’s t-test indicated no difference () between the levels of each group before and after treatment.